Phase I study of oral nintedanib combined with docetaxel in previously treated Japanese patients with advanced non-small cell lung cancer (NSCLC)

被引：0

作者：

Okamoto, I. ^{[1
,2
,3
]}

Miyazaki, M. ^{[4
]}

Takeda, M. ^{[4
]}

Azuma, K. ^{[4
]}

Hayashi, H. ^{[4
]}

Seto, T. ^{[5
]}

Konishi, K. ^{[6
]}

Sarashina, A. ^{[7
]}

Kaiser, R. ^{[8
]}

Nakagawa, K. ^{[4
]}

机构：

[1] Kinki Univ Hosp, Fukuoka, Japan

[2] Kyushu Univ Hosp, Fukuoka 812, Japan

[3] Kyushu Univ Hosp, Ctr Clin & Translat Res, Fukuoka 812, Japan

[4] Kinki Univ, Sch Med, Osaka 589, Japan

[5] Kyushu Natl Canc Ctr, Fukuoka, Japan

[6] Nippon Boehringer Ingelheim Co Ltd, Oncol Clin Res, Shinagawa Tokyo, Japan

[7] Nippon Boehringer Ingelheim Co Ltd, Med Dev Div, Kobe, Hyogo, Japan

[8] Boehringer Ingelheim Pharma GmbH Co KG, Biberach, Germany

来源：

EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3506

引用

页码：S830 / S831

页数：2

共 50 条

[1] Phase I/II study of weekly docetaxel in patients with previously treated non-small cell lung cancer (NSCLC).
Hirata, T
Kawashita, F
Ogawa, E
Masago, K
Kato, M
Takada, M
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 676S - 676S
[2] Feasibility Study of Nivolumab and Docetaxel in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
Shimokawa, T.
Nakamura, Y.
Iwasawa, S.
Miyazaki, K.
Yamanaka, T.
Takiguchi, Y.
Okamoto, H.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2431 - S2431
[3] Phase I Study of Nivolumab and Ipilimumab Combined with Nintedanib in Advanced Non-Small Cell Lung Cancer
Puri, S.
Guadalupe, N. Rodriguez
Niyongere, S.
Boyle, T.
Thapa, R.
Chen, D.
Noyes, D.
Chatwal, M.
Antonia, S.
Gray, J. E.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S640 - S641
[4] Feasibility study of nivolumab and docetaxel in previously treated patients with advanced non-small cell lung cancer
Miyazaki, Kazuhito
Iwasawa, Shunichiro
Nakamura, Yukiko
Shimokawa, Tsuneo
Yamanaka, Takeharu
Takiguchi, Yuichi
Okamoto, Hiroaki
ANNALS OF ONCOLOGY, 2017, 28
[5] Efficacy and safety of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC)
Wang, Z.
Han, X.
Guo, J.
Zhu, D.
Zhang, X.
Tang, X.
Meng, X.
ANNALS OF ONCOLOGY, 2020, 31 : S1400 - S1400
[6] Phase I study of apatinib combined with docetaxel in EGFR-negative advanced non-small cell lung cancer (NSCLC)
Duan, Jianchun
Wang, Jie
Wang, Zhijie
Lin, Lin
Li, Junling
Wang, Yan
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[7] Impact of EGFR Mutation on Clinical Outcome of Nintedanib plus Docetaxel in Previously Treated Non-Small Cell Lung Cancer (NSCLC)
Hong, S.
Ahn, H. J.
Kim, K. H.
Lee, S. S.
Lee, Y. G.
Yuh, Y. J.
Cheon, P. I.
Chae, Y. S.
Jang, T. W.
Kang, J.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2134 - S2135
[8] A phase IINCCTG study of irinotecan and docetaxel in previously treated patients with non-small cell lung cancer
Molina, Julian R.
Nikcevich, Daniel
Hillman, Shauna
Geyer, Susan
Drevyanko, Timothy
Jett, James
Verdirame, Joseph
Tazelaar, Henry
Rowland, Kendrith
Wos, Edward
Kutteh, Leila
Nair, Suresh
Fitch, Tom
Flynn, Patrick
Stella, Philip
Adjei, Alex A.
CANCER INVESTIGATION, 2006, 24 (04) : 382 - 389
[9] PEMETREXED MONOTHERAPY FOR JAPANESE PATIENTS WITH PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCER (NSCLC)
Sato, Akira
Misumi, Yuki
Kashizaki, Fumihiro
Ishii, Mari
Shimokawa, Tsuneo
Hida, Naoya
Okamoto, Hiroaki
JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1213 - S1214
[10] Tolerability of Nintedanib (BIBF 1120) in Combination with Docetaxel: A Phase 1 Study in Japanese Patients with Previously Treated Non-Small-Cell Lung Cancer
Okamoto, Isamu
Miyazaki, Masaki
Takeda, Masayuki
Terashima, Masaaki
Azuma, Koichi
Hayashi, Hidetoshi
Kaneda, Hiroyasu
Kurata, Takayasu
Tsurutani, Junji
Seto, Takashi
Hirai, Fumihiko
Konishi, Koichi
Sarashina, Akiko
Yagi, Nobutaka
Kaiser, Rolf
Nakagawa, Kazuhiko
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (02) : 346 - 352

← 1 2 3 4 5 →